A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2014
At a glance
- Drugs Bortezomib; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 01 Dec 2011 Actual patient number is 55 according to ClinicalTrials.gov.
- 04 Apr 2011 End date added from ClinicalTrials.gov
- 04 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.